Kidney cancer occurs due to the mutations that make them cancerous. Around 76,083 people are diagnosed with kidney cancer as per the reports of the American Cancer Society’s 2021. Out of that, 27,300 women and 48,789 men are expected to develop the disease condition. Estimates also show that around 13,780 people (4,990 women and 8,790 men) are expected to die from kidney cancer. It is the ninth most common cancerous condition in women. It is twice more prevalent in men than in women. The lifetime risk of men developing kidney or renal pelvis cancers is estimated at around 1 in 46 (about 2.02%), and that of women is only around 1 in 80 (1.03%). People belonging to the age group of 65 to 74 are developing kidney cancers. American Indians/Alaska natives and Afro Americans are more prone to developing kidney cancer. If we consider the years 2008 to 2017, the rates of kidney cancers have increased by 1% each year. But due to the timely diagnosis and apt treatment strategies, deaths due to kidney cancer between 2009 and 2018 have reduced by around 1%. The 5-year survival rate of people diagnosed with kidney cancer is estimated at 75%.
Kidney Cancer Statistics
Kidney cancer occurs when cells in the kidney region undergo mutations and become cancerous. As per the American Cancer Society’s 2021 estimates of kidney cancer, around 76,083 people will be diagnosed with the disease. Out of that, 27,300 women and 48,789 men are expected to develop the disease condition 1. Estimates also show that around 13,780 people (4,990 women and 8,790 men) are expected to die from kidney cancer.
Out of the ten most common cancer conditions, kidney cancer is one. Kidney cancer is considered the sixth most common cancerous condition found in men. It is the ninth most common cancerous condition in women. Kidney cancer is twice more prevalent in men than in women. the lifetime risk of men developing kidney or renal pelvis cancers is estimated at around 1 in 46 (about 2.02%), and that of women is only around 1 in 80 (1.03%).
Commonly, people belonging to the age group of 65 to 74 are developing kidney cancers. The average age at which most people are diagnosed with kidney cancer is 64. The cancerous condition is not common in people below 45 years of age. The chance of the disease increases with age. Also, American Indians/Alaska natives and Afro Americans are more prone to developing cancer 2. The numbers mentioned applies to all kinds of kidney and renal pelvis cancer conditions.
The number of people diagnosed with kidney cancer increases with each passing decade. But with better treatment facilities and care options, many improvements have happened in managing this cancer condition. If we consider the years 2008 to 2017, the rates of kidney cancers have risen by 1% each year. Imaging tests (like CT scans) have played a significant role in detecting kidney cancers. Imaging tests can detect even the most minor tumours in the kidney, even when the tests are done for some other medical conditions. Due to timely diagnosis and apt treatment strategies, deaths due to cancer between the years 2009 and 2018 has decreased by around 1%.
WHAT IS 5-YEAR RELATIVE SURVIVAL RATE?
Survival rates are estimates based on previous outcomes of larger numbers of people who had a specific cancerous condition. It is important to note that the survival rate does not predict the future or what will happen in any particular person’s case.
Five-year survival rate gives an idea of what percentage of people with an identical type, stage and grade of kidney cancer (or any cancer) are still alive a certain amount of time (taken as five years) after they were diagnosed with the disease. Analysing this will help give people a better understanding of how likely their treatment will be successful and their chances of survival against the disease.
In relative survival rate, people with a particular cancer type and the stage are compared against the overall population. The 5-year survival rate of people diagnosed with kidney cancer is estimated at around 75% 3.
In this cancer cases, where cancer has not invaded other tissues or organs, the five-year survival rate is estimated as 93%. About two-thirds of people with kidney cancers are diagnosed at this stage. For kidney cancers that have invaded surrounding tissues and organs or regional lymph nodes, the 5-year survival rate is estimated as around 70%. Regarding distant metastasis of cancerous growth in the kidney, the 5-year survival rate is calculated as 13%.
Studies and researches are still analysing the different traits of kidney cancers- the size of the tumour, its stage, grade, type, its gravity, whether it is capable of affecting the lymph nodes etc., to devise the survival rate of the disease. Most of the time, survival rates are calculated post-surgical procedures for these cancers. And the studies claim that people with a kidney tumour capable of distant metastasis or can affect the lymph nodes have low survival rates. But the recent advancements in treatments (like immunotherapy) and technologies provide a new ray of hope to people diagnosed with metastatic advanced kidney cancer.
It is important to note that the figures mentioned in this article are estimates that can vary with time. Also, the 5-year survival data may not portray the outcomes of better diagnosis or best treatment options available. Patients are encouraged to talk with their health care provider to know more and in detail regarding kidney cancer.
- 1.Scelo G, Larose TL. Epidemiology and Risk Factors for Kidney Cancer. JCO. Published online December 20, 2018:3574-3581. doi:10.1200/jco.2018.79.1905
- 2.Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. Published online September 12, 2018:394-424. doi:10.3322/caac.21492
- 3.Mangone L, Bossard N, Marcos-Gragera R, Pezzarossi A, Roncaglia F, Giorgi Rossi P. Trends in net survival from kidney cancer in six European Latin countries: results from the SUDCAN population-based study. European Journal of Cancer Prevention. Published online January 2017:S121-S127. doi:10.1097/cej.0000000000000297